Greenbaum Dov
Sanford T Colb & Co., Intellectual Property Law, 4 Shaar Hagai, Marmorek, Rehovot, Israel.
Recent Pat DNA Gene Seq. 2011 Dec;5(3):153-65. doi: 10.2174/187221511797636284.
The Federal Circuit uses particular patent doctrines as policy levers to control the nature of the nation's patent output. To this end, the Court will actively discriminate in it's application of the Patent Act, depending on the nature of the technology before it. One example of such a lever is the written description doctrine. Most recently, the court has looked to this doctrine in an effort to limit the scope of biotechnology patents in general and DNA patents in particular. This paper provides a cursory review of this law regarding the enigmatic written description requirement, examining particularly its history and purposes. It then examines some of the recent cases that allude to the Federal Circuit's particular efforts in the biotechnology industry. Finally, it presents a potentially problematic technology for future implementation of discriminatory practices by the court.
联邦巡回上诉法院将特定的专利原则用作政策杠杆，以控制美国专利产出的性质。为此，法院会根据其面前技术的性质，在适用《专利法》时积极进行区分。这种杠杆的一个例子就是书面描述原则。最近，法院参照这一原则，试图总体上限制生物技术专利的范围，尤其是DNA专利的范围。本文对关于神秘的书面描述要求的这一法律进行了简要回顾，特别考察了其历史和目的。然后，本文研究了一些最近的案例，这些案例提及了联邦巡回上诉法院在生物技术行业的具体举措。最后，本文提出了一项可能给法院未来实施歧视性做法带来问题的技术。
